June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Debridement- Scaling, Moist-Heat Therapy and Meibomian Gland Expression in the Treatment for Evaporative Dry Eye.
Author Affiliations & Notes
  • Paloma Lopez
    Centro Medico Zambrano Helion, Monterrey, Mexico
  • Jorge E. Valdez-Garcia
    Centro Medico Zambrano Helion, Monterrey, Mexico
  • Julio C Hernandez
    Centro Medico Zambrano Helion, Monterrey, Mexico
  • Denise Loya
    Centro Medico Zambrano Helion, Monterrey, Mexico
  • Footnotes
    Commercial Relationships   Paloma Lopez, None; Jorge E. Valdez-Garcia, None; Julio Hernandez, None; Denise Loya, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2248. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paloma Lopez, Jorge E. Valdez-Garcia, Julio C Hernandez, Denise Loya; Debridement- Scaling, Moist-Heat Therapy and Meibomian Gland Expression in the Treatment for Evaporative Dry Eye.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2248.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Report the effectiveness in reducing evaporative dry eye signs and symptoms with palpebral therapy consisting of: debridement- scaling, heat therapy and meibomian gland expression.

Methods : Patients with evaporative dry eye where referred to the palpebral therapy sessions from January 2016 to November 2016. Palpebral therapy consisted of 3 sessions once a week where patient underwent debridement- scaling of the lid margin (prior to lissamine green staining), followed by moist-heat therapy with Blephasteam® during 10 minutes and meibomian gland expression (triple therapy) and topical preservative-free sodium hyaluronate 0.15% only. All patients summited the Ocular Surface Disease Index (OSDI) questionnaire on their first session and where asked to repeat ending the 3 week treatment. Tear break up time and corneal staining score (NEI scale) was also measured and recorded using fluorescein the first session and at the end of treatment. T test to compare means and variance analysis were used, p<.05 was considered statistically significant.

Results : A total of 186 eyes (93 patients) were included. Mean age was 54.95±17.23 years, 58% were female. Ocular surface disease other than posterior blepharitis was present in 13.9% of the eyes. Topical antibiotics and topical steroids were previously used by 12.9% and 13.1% of the patients, respectively. 13.97% of the patients were on previous treatment with oral tetracyclines. Pre-treatment corneal staining score (NEI scale), tear break up time (seconds) and OSDI score were 1.14±1.59, 6.57±2.17 and 28.36±19.21 respectively. Post-treatment corneal staining score (NEI scale), tear break up time and OSDI score were 0.27±0.69, 7.75±1.93 and 14.32±12.91 (p<.001, p<.001 and p<.001, respectively). Variance analysis showed a positive effect of using oral tetracyclines previous to the triple treatment on the OSDI score (p=.03, n2=0.126). No adverse effects were observed.

Conclusions : Triple therapy for evaporative dry eye showed a significant decrease in OSDI score and an improvement on TBUT as well as on corneal staining score after the three week therapy. Previous treatment with oral tetracycline was associated with increased improvement on OSDI score.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×